

Name	Affiliation	Email	Secondary Emails	Major Area(s) of Interest	SIG Liaison
Wan-Ting Huang	Taiwan Centers for Disease Control	pecuchet@gmail.com	muagi@cdc.gov.tw	Infectious Disease Epidemiology, Pharmacoepidemiology, Pediatrics, Vaccines	
Edward Chia-Cheng Lai	School of Pharmacy, National Cheng Kung University, Tainan, Taiwan	Edward_lai@mail.ncku.edu.tw		Psychiatry, Neurology, Pediatrics, Geriatrics, International Pharmacoepidemiologic Study	AsPEN
Madlen Gazarian, MBBS, MSc, FRACP	University of NSW, Sydney	m.gazarian@unsw.edu.au		Paediatrician, Clinical Pharmacology & Therapeutics, Clinical Epidemiology & Health Services Research, Pharmacoepidemiology & Pharmacovigilance	
Andrea Margulis MD ScD	RTI Health Solutions	andrea.margulis@gmail.com	amargulis@rti.org; andreamargulis@post.harvard.edu ;	Pharmacoepidemiology, pediatrics, vaccines, drug safety in pregnancy	
Florentia Kaguelidou, MD, PhD	Paris Diderot University-APHP	florentia.kaguelidou@aphp.fr		pharmacoepidemiology, drug utilization	

Veronique De Smet	Clinical Pharmacist	veronique.desmet@uzgent.be		off label medication, pediatric formularies	
Genevieve Durrieu	Clinical Pharmacologist, University of Toulouse France	genevieve.durrieu@univ-tlse3.fr		drug safety, off label drug use	
Esme Baan	Erasmus University, Rotterdam	e.baan@erasmus.nl		asthma therapy in children	
Ibrahim Oreagba	University of Lagos, Nigeria	iaoreagba@cmul.edu.ng		pharmacovigilance, clinical pharmacology	
Miriam Sturkenboom	University Medical Center, Utrecht	mcjm.sturkenboom@gmail.com	cgr.sturkenboom@gmail.com	methods, pediatric databases, vaccines	Vaccine, Database
Osemeke Osokogu	Erasmus Medical Center	oosokogu@gmail.com		methods exposures, outcomes	
James Feinstein MD MPH	University of Colorado School of Medicine	james.feinstein@ucdenver.edu		Polypharmacy, Drug-Drug Interactions, Complex Chronic Diseases, Epidemolysis Bullosa	

Bruce Carleton PharmD	University of British Columbia Faculty of Medicine	bcarleton@popi.ubc.ca		Pharmacoepidemiology, pharmacogenomics, complex diseases	
Susan dosReis, PhD	University of Maryland School of Pharmacy	sdosreis@rx.umaryland.edu		Psychotropic utilization and outcomes; mulit-morbidity, foster care and vulnerable populations	
Al Artaman, MD PhD MHA	University of Manitoba College of Medicine	artamana@umanitoba.ca		Cancer, perinatal, global health epidemiology	Oncology
Tamar Lasky, PhD, FISPE	MIE Resources	Tamar.Lasky@fda.hhs.gov	tlasky@mie-epi.com	Pain medications, antibiotics, drug utilization, real world evidence, policy, vaccines	
Jonathan Slaughter, MD MPH	Nationwide Children's Hospital/The Ohio State University	slaughtj@gmail.com		Neonatal Pharmacoepidemiology, Neonatal Outcomes Research, Neonatal Comparative Effectiveness Research	
Alan Kinlaw, PhD	University of North Carolina at Chapel Hill	akinlaw@unc.edu		Antibiotic utilization and stewardship, respiratory diseases, vaccines, causal inference	

Daniel B. Horton MD MSCE	Rutgers University	daniel.horton@rutgers.edu		Glucocorticoids, antibiotics, pediatric rheumatology, juvenile idiopathic arthritis	
O'Mareen Spence, MPH	University of Maryland School of Pharmacy	ospence@umaryland.edu		Pharmacoepidemiology; psychotropic utilization; pediatrics;	
Lina Titievsky, PhD MPH	Epidemiology, Worldwide Safety and Strategy, Pfizer Inc	lina.titievsky@pfizer.com		pharmacoepidemiology; vaccines; medicines in pregnancy; impact of in utero exposures on adult health; study design/methods	Vaccines
Sudha Raman	Duke University	sudha.raman@duke.edu		Psychotropic medications, EHR-data quality	Database
Dinci Pennap, PhD, MPH	US Food and Drug Administration and University of Maryland Baltimore	dpennap@umaryland.edu		pharmacoepidemiology; pediatric mental health; psychotropic medication utilization and health disparities	
Mehmet Burcu, PhD, MS	Merck Co., Inc (Merck, Sharp, and Dohme)	mehmet.burcu@merck.com	mburc001@umaryland.edu	Novel uses of real world evidence (e.g., external control arms), drug safety and outcomes, causal inference, health policy, drug utilization, psychiatry, and cancer	

Julie M. Zito, PhD, FISPE	University of Maryland, Baltimore	jzito@rx.umaryland.edu		drug utilization, drug safety, mental health, psychotropic medications, and health policy	
Wendy Camelo Castillo, MD MSc PhD	University of Maryland, Baltimore	wcastillo@rx.umaryland.edu		Comparative effectiveness, multimorbidity, mental health, medications in pregnancy	
Ann W. McMahon, MD, MS	Food and Drug Administration, Silver Spring, Maryland	ann.mcmahon@fda.hhs.gov		Pediatric pharmacoepidemiology, pediatric drug safety, pediatric post-marketing safety surveillance. Pediatric postmarketing databases	
Greta Bushnell, MSPH	University of North Carolina at Chapel Hill	gb2612@cumc.columbia.edu	gbushnel@live.unc.edu	Psychotropic medications, pediatrics, pharmacoepidemiology	Adherence
Rachel E. Sobel, DrPH	Pfizer Inc	rachel.sobel@pfizer.com		Pediatric pharmacoepidemiology, pediatric drug safety, pediatric post-marketing safety surveillance, pediatric registries, Public-private partnerships.	BRACE
Geert tJong, MD, PhD	University of Maitoba	geert.tjong@umanitoba.ca		clinical pharmacology, pharmacoepidemiology	

Paul Bakaki	Case Western Reserve University	pmb18@case.edu		polypharmacy	
Lauren Kelley, PhD, CCRP	University of Manitoba	lauren.elyse.kelly@gmail.com		clinical trial methodology, systematic reviews, opioids, neonatal drug development	
Stuart MacLeod, MD, PhD	University of British Columbia	smacleod@bcchr.ca		drug policy research, clinical pharmacology, global child health	
Rachel Harrington	University of Illinois Chicago	rharr26@uic.edu		Cancer survivorship, pediatrics, multimorbidity and polypharmacy	
Oliver Scholle, MSc	Leibniz Institute for Prevention Research and Epidemiology	scholle@leibniz-bips.de		Drug utilization, mental health, drug safety, psychotropic medications	
Jenny Sun, MS	Harvard University	jennysun@g.harvard.edu		Drug safety, databases, methods, psychotropic medications	
Steven Bird	US FDA	Steven.Bird@fda.hhs.gov		Drug safety, utilization	

Claudia G.S. Osorio de Castro	National School of Public Health (FIOCRUZ-MOH), Brazil	claudiaosorio.soc@gmail.com		Public health, drug policy research	
Szu-Ta Chen (Starr)	Harvard University	szutachen@hsph.harvard.edu		Pediatrics	
Olessia Zorina	Novartis Pharmaceuticals	olessia.zorina@novartis.com		Pediatrics, drug safety, drug utilization	
Francesca Kolitsopoulos	Pfizer	Francesca.Kolitsopoulos@Pfizer.com			
Carmen Ferrajolo		carmen.ferrajolo@unicampania.it			
Sigalit Kaplan, PhD	Teva Pharmaceuticals	Sigalit.Kaplan@teva.co.il			
Dimitri Bennett	Takeda Pharmaceuticals	Dimitri.Bennett@takeda.com			

Sigrid Behr	Novartis Pharmaceuticals	Sigrid.behr@novartis.com			
Stephen Crystal, PhD	Rutgers University	scrystal@rci.rutgers.edu			
Tobias Gerhard, PhD	Rutgers University	tgerhard@ifh.rutgers.edu			
Osemeke U. Osokogu, MD, MPH, MSc, PhD	AMREF	oosokogu@gmail.com			
Judy Staffa	FDA	judy.staffa@fda.hhs.gov			
Andy Mosholder	FDA	andrew.mosholder@fda.hhs.gov			
Emre Yucel	AMGEN	pharmemreyucel@gmail.com			

Allen Mitchel	Boston University	allenmit@bu.edu			
Christian Hampp	FDA	christian.hampp@fda.hhs.gov			
Caitlin Knox	UFL and IQVIA	cknox@ufl.edu			
Linda Wijlaars	University College London	linda.wijlaars.10@ucl.ac.uk			
Vani vannappagari	GSK	vani.x.vannappagari@gsk.com			
Dina Gifkins	Johnson and Johnson	Dgifkins@its.jnj.com			
Sumitra Shantakumar	GSK	sumitra.y.shantakumar@gsk.com			

Angela Czaja	Columbia University	Angela.Czaja@childrenscolorado.org			
Bethany Baer	US FDA	Bethany.Baer@fda.hhs.gov			
Ibrahim Oreagba	University of Lagos	iaoreagba@cmul.edu.ng			
Arti Virkud	UNC	avirkud@live.unc.edu			
Tim Beukelman	University of Alabama	tbeukelman@peds.uab.edu			
Susan Oliveria	IQVIA	Susan.Oliveria@iqvia.com			
Claudia Becker	Basel Pharmacoepidemiology Unit Div. of Clin. Pharmacy & Epidemiology	Claudia.Becker@usb.ch			

	Department of Pharmaceutical Sciences, University Basel				
Monique Falconer	Division of Epidemiology II Office of Pharmacovigilance and Epidemiology Office of Surveillance and Epidemiology Center for Drug Evaluation and Research U.S. Food and Drug Administration	Monique.Falconer@fda.hhs.gov			